EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Evidence of Growth Improvement in Children 1 to 5 Years of Age Receiving Enteral Formula Administered Through an Immobilized Lipase Cartridge

Alvin Jay Freeman iD, Elizabeth Reid iD, Terri Schindler iD, Thomas J Sferra iD, Barbara Bice iD, Ashley Deschamp, Heather Thomas, David P Recker, Ann E Remmers iD

Nutrients · 2026

DOI: 10.3390/nu18020287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2026. Verfasst von Alvin Jay Freeman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Enteral Nutrition, Lipase, Enzymes, Immobilized, Infant Formula. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alcresta Therapeutics, Alcresta Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: RELiZORB immobilized lipase cartridge (ILC) is a single-use digestive enzyme cartridge that connects in-line with enteral feeding circuits to hydrolyze triglycerides in enteral formulas. It is cleared by the FDA for pediatric and adult use. Limited data have been published regarding the effect of ILC use on growth in children younger than 5 years of age.

Methods

We performed a retrospective evaluation of real-world data extracted from a third-party reimbursement program database. All patients in the program database who initiated ILC use with enteral formula when 1 to 4 years of age between 2019 and 2023 were included. Baseline and follow-up weight, height/length, and body mass index (BMI) data were collected for up to 12 months.

Results

A total of 186 patients from 90 clinics in the United States were included. A subset (143 patients) with baseline and follow-up growth measurements was included in the efficacy analysis population; 76% were diagnosed with cystic fibrosis. Mean weight and BMI z-scores improved significantly (0.63 [p < 0.001] and 0.53 [p = 0.006], respectively) from baseline to 12 months after initiation of ILC use. Significant improvement in the mean weight z-score was observed after 3 months. Among people with cystic fibrosis (pwCF) who initiated ILC use when 2 to 4 years of age, those with a BMI ≥ 50th percentile increased from 22% at baseline to 43% after 12 months (p = 0.021). Improvement in weight-for-length was also observed in 1-year-old pwCF.

Conclusions

Real-world evidence showed that initiation of ILC use was associated with significant improvements in mean weight and BMI z-scores among young children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enteral NutritionLipaseEnzymes, ImmobilizedInfant FormulaChild DevelopmentHumansChild, PreschoolInfantRetrospective StudiesFemaleMaleCystic FibrosisBody Mass IndexTriglyceridesBody Weight

Stichwörter der Autor:innen

cystic fibrosisenteral nutritionfat malabsorptionlipasepediatricshort bowel syndrome

Substanzen

LipaseEnzymes, ImmobilizedTriglycerides

Autor:innen und Institutionen

  • Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43210, USA.
  • Division of Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH 43205, USA.
  • Department of Clinical Nutrition, Cystic Fibrosis Center, Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Division of Pediatric Pulmonology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.
  • Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, UH Rainbow Babies & Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
  • Nebraska Regional Pediatric Cystic Fibrosis Center at Children's Nebraska, Omaha, NE 68114, USA.

ORCID-Profile: Alvin Jay Freeman, Elizabeth Reid, Terri Schindler, Thomas J Sferra, Barbara Bice, Ann E Remmers

Förderung

  • Alcresta Therapeutics
  • Alcresta Therapeutics, Inc.

Zitieren

APA

Freeman, A. J., Reid, E., Schindler, T., Sferra, T. J., Bice, B., Deschamp, A., Thomas, H., Recker, D. P., & Remmers, A. E. (2026). Real-World Evidence of Growth Improvement in Children 1 to 5 Years of Age Receiving Enteral Formula Administered Through an Immobilized Lipase Cartridge. Nutrients. https://doi.org/10.3390/nu18020287

Vancouver

Freeman AJ, Reid E, Schindler T, Sferra TJ, Bice B, Deschamp A, et al. Real-World Evidence of Growth Improvement in Children 1 to 5 Years of Age Receiving Enteral Formula Administered Through an Immobilized Lipase Cartridge. Nutrients. 2026. doi:10.3390/nu18020287

BibTeX
@article{Freeman2026,
  author = {Freeman, Alvin Jay and Reid, Elizabeth and Schindler, Terri and Sferra, Thomas J and Bice, Barbara and Deschamp, Ashley and Thomas, Heather and Recker, David P and Remmers, Ann E},
  title = {Real-World Evidence of Growth Improvement in Children 1 to 5 Years of Age Receiving Enteral Formula Administered Through an Immobilized Lipase Cartridge},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18020287}
}
Kostenlos starten →